All News

RheumNow Podcast square

Anti-Drug Antibodies with Biologics (7.14.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Read Article
artangiogca.jpg

GCA and the Risk of Cerebrovascular Ischemic Events

Jack Cush, MD

Cerebrovascular ischemic events (CIE) can be one of the most severe complications of giant cell arteritis (GCA), but is seen in 4-5% of GCA patients according to a recent French University Hospital. 

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

ICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting

Jack Cush, MD

A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.

Read Article
back, LBP, spine, AS

Opioids Ineffective in Acute Lower Back and Neck Pain

EurekAlert!

A randomised controlled trial including 347 participants with lower back or neck pain found there was no benefit of taking opioid pain relievers compared to placebo. 

Read Article
RheumNow Podcast square

How Often Do You Monitor MTX? (6.16.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com, including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. 

Read Article
depression oh no HA

Why Depression Screening Should be Mandatory at Each Visit

Jack Cush, MD

Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015. 

Read Article
JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis". Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/fGgTLWj8Hc https://t.co/65hpkI8oo0

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA has a review of "Diagnosis and Treatment of Hip and Knee Osteoarthritis". Affecting 240 million people worldwide, >32 million in the US. OA Risk factors include age, female, obesity, genetics, & trauma/injury. OA pts have more comorbidities https://t.co/ee10MKIqUp https://t.co/N2i3VWgvc9

Links:

Dr. John Cush RheumNow ( View Tweet)
NIH MOST study 2093 OA pts w/ Knee Xrays/CT/Pain scores q8 mos x2 yrs. IA mineralization seen in 10% knees & assoc w/ a 2 fold higher risk of freq knee pain & OR 1.86 of freq intermit/constant pain. IA mineralz. meniscus or Jt capsule=higher odds of pain https://t.co/CacJ40DVyL https://t.co/Zhwv98d6Pe

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @Janetbirdope : What would you do? A middle aged woman has pain and impaired hand function with her PIP&DIP erosive hand #osteoarthritis? Exam - jts are tender w soft tissue swelling? #NSAIDs, #denosumab, #methotrexate? 🤷‍♀️ A +RCT of #MTX in #erosive #hand #OA at #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

c-Fos regulates chondrocyte proliferation and differentiation, and cFOS-positive chondrocytes were increased in human and murine OA cartilage. New research (humans an mice) suggests it plays a role in protecting cartilage and could be a therpeutic target https://t.co/B0tmo0AbQe https://t.co/KPrOm3Spfa

Links:

Dr. John Cush RheumNow ( View Tweet)
Ultrasonography May Improve OA Pain Prediction Dr. Bella Mehta reports on POS0107 from EULAR 2023 in Milan, Italy. https://t.co/ZHBdWPWTys https://t.co/JLIScNVZGB

Links:

Dr. John Cush RheumNow ( View Tweet)
Australian CRISTAL RCT 23 458 OA adults undergoing hip or knee replacements & given ASA 100 mg/d or SC enoxaparin 40 mg qd for 35 days (THR) or 14 days(TKR) for VTE prophylaxis = no difference betw groups: 90D mortality was 1.67% vs 1.53% https://t.co/wBLtlyCcsF https://t.co/WFkZ2KNHFF

Links:

Dr. John Cush RheumNow ( View Tweet)
519 pts in the Hand OSTeoArthritis in Secondary care (HOSTAS) cohort studied & 17% had prolonged morning stiffness (>60 min); mild in 30%, intermediate in 37%, severe in 18% and extreme in 4%. Assoc w/ more pain, worse function and QOL https://t.co/6LSir7nSae https://t.co/lhoxwpfuqD

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Denosumab in hand OA prevented erosions! #eular2023 @RheumNow https://t.co/Ij2CVjh1ET
Bella Mehta bella_mehta ( View Tweet)
#EULAR2023 Clinical Highlights. Osteoarthritis. OP0071 Single centre Phase 2 RCT showed Denosumab halted erosion in Erosive OA at 24 weeks treatment, and the treatment effect enhances after 48 weeks vs PBO @RheumNow https://t.co/YWFUg3cp7P
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nocicpetor ablation in mice model with #OA - pain was reduced. If its done before OA progression, it helps, but after it doesnt! @AM_Malf work highligted at #EULAR2023 @RheumNow https://t.co/zvxHmlCIrD
Bella Mehta bella_mehta ( View Tweet)
We need to assess CV risk in IA but how? Performances of QRisk3, Framingham & Reynolds scores for prediction of CV event in OA RA PsA AS PSO Bummer: these 3 prediction tools are less accurate in IA but also OA. We need a dedicated tool. @Rheumnow OP0267 #EULAR23 https://t.co/O73cETXXoe
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting study presented by Dr Kent Kwoh in #KneeOA using the OAI data - effusion-synovitis produced heterogenous effects on pain reporting depending on the activity - walking, stairs, standing etc. effect not in bone marrow lesions @rheumnow abst#POS0108 #EULAR2023 https://t.co/MvI5z1KHlE
Bella Mehta bella_mehta ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×